DCTN5 encodes dynactin subunit 5, a component of the dynactin complex that activates dynein, the primary minus-end-directed molecular motor for ultra-processive microtubule-based transport 1. DCTN5 localizes to the centrosome and cytosol, functioning as part of the multi-subunit dynactin machinery essential for intracellular cargo transport. In disease contexts, DCTN5 expression has been implicated in multiple pathologies. Notably, low DCTN5 mRNA expression correlates with favorable overall survival in cutaneous melanoma patients, suggesting a role in cancer progression 1. DCTN5 interacts with microRNAs through transposable element-derived regulatory regions and has been associated with breast cancer pathogenesis 2. In renal disease, DCTN5 expression is critical for cilia integrity; Dctn5 downregulation occurs in glomerulocystic kidney disease models, indicating involvement in ciliary function and polycystic kidney disease pathogenesis 3. Additionally, DCTN5 has been identified as a bipolar disorder susceptibility gene, with knockdown disrupting neuronal network physiology in vitro 4. Clinically, genetic variants affecting DCTN5 expression in skeletal muscle (rs722069) are associated with exercise intervention dropout, suggesting involvement in metabolic and behavioral responses to physical training 5. These findings position DCTN5 as a multifunctional protein relevant to cancer prognosis, psychiatric genetics, renal disease, and metabolic health.